Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.42 |
| ▸ | F9 | P00740 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30363971 | 1.00 | ABL1 (0.54) | ABL1BCRMAOASCN5ACA12 | |
| SCHEMBL21770975 | 0.87 | XDH (0.51) | ABL1BCRMAOAMAP4K4CYP3A4 | |
| SCHEMBL29628993 | 0.87 | SCN5A (0.54) | ABL1BCRSCN5ACA12CA9 | |
| SCHEMBL1337217 | 0.82 | TAAR1 (0.52) | TAAR1CYP3A4KIF11 | |
| SCHEMBL1242144 | 0.81 | KIF11 (0.52) | SCN5ATAAR1CYP3A4AURKATPX2 | |
| SCHEMBL1271679 | 0.79 | MAOA (0.64) | MAOACA12CA9CA1CA2 | |
| SCHEMBL1523 | 0.79 | CYP3A4 (0.54) | ABL1BCRSCN5ACYP3A4KIF11 | |
| Hydrochloric Acid SCHEMBL29386875 | 0.79 | KIF11 (0.50) | SCN5ACYP3A4AURKATPX2KIF11 | |
| SCHEMBL29366090 | 0.79 | CYP3A4 (0.54) | ABL1BCRSCN5ACYP3A4KIF11 | |
| SCHEMBL1241773 | 0.79 | MAOB (0.63) | ABL1BCRMAOASCN5ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| WO-2012131501-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AS COT KINASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-10-04 | — | — | WO | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884234-B2 | N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| WO-2009125606-A1 | PAI-1 INHIBITOR | 株式会社医薬分子設計研究所 (JP) | 2009-10-15 | — | — | WO | disclosed |
| US-20090203585-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. | 2009-08-13 | — | — | US | disclosed |
| EP-2072498-A1 | N-PHENYLOXAMIDIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-06-24 | — | — | EP | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| WO-2007130743-A2 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-7294616-B2 | Capreomycin derivatives and their use as antibacterials | ARRAY BIOPHARMA, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| WO-2006052499-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060094644-A1 | Capreomycin derivatives and their use as antibacterials | ARRAY BIOPHARMA, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20020177594-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
| US-20020103192-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | ABL1 3591/4885BCR 3261/4885MAOA 107/4885 |
| US-20020103192-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC4 | ABL1 2882/4885BCR 2210/4885MAOA 2336/4885 |
| US-20090203585-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | CAPRIN1, NISCH, RPIA | ABL1 3154/4885BCR 2362/4885MAOA 2554/4885 |
| US-20020177594-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC3 | ABL1 2795/4885BCR 3462/4885MAOA 1132/4885 |
| US-20060094644-A1 | Capreomycin derivatives and their use as antibacterials | SPOUT1, CAPRIN1, FBL | ABL1 3839/4885BCR 3450/4885MAOA 1940/4885 |
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | ABL1 3997/4885BCR 3680/4885MAOA 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.